Sintx Technologies Announces Board Chairman Transition
Sintx Technologies (NASDAQ: SINT) announced a significant leadership transition as Dr. Sonny Bal retires from his position as Chairman of the Board, with CEO Eric Olson unanimously appointed as the new Chairman, effective immediately.
Dr. Bal, who served as Chairman since 2015, will remain on the Board of Directors to ensure continuity. Under his leadership, Sintx underwent transformation in the advanced materials sectors, particularly focusing on high-value medical applications and strategic partnerships.
Eric Olson, who became CEO in August 2024, brings experience in medical device and industrial sectors. His appointment as Chairman aligns with the company's strategy to accelerate commercialization, enhance financial discipline, and explore strategic initiatives including partnerships, licensing, and M&A opportunities.
Sintx Technologies (NASDAQ: SINT) ha annunciato una significativa transizione nella leadership, poiché il Dr. Sonny Bal si ritira dalla sua posizione di Presidente del Consiglio, con l'Amministratore Delegato Eric Olson nominato all'unanimità come nuovo Presidente, con effetto immediato.
Il Dr. Bal, che ha ricoperto il ruolo di Presidente dal 2015, rimarrà nel Consiglio di Amministrazione per garantire continuità. Sotto la sua guida, Sintx ha subito una trasformazione nei settori dei materiali avanzati, concentrandosi in particolare su applicazioni mediche ad alto valore e partnership strategiche.
Eric Olson, che è diventato CEO nell'agosto 2024, porta con sé esperienza nei settori dei dispositivi medici e industriali. La sua nomina a Presidente è in linea con la strategia dell'azienda di accelerare la commercializzazione, migliorare la disciplina finanziaria ed esplorare iniziative strategiche, tra cui partnership, licenze e opportunità di fusioni e acquisizioni.
Sintx Technologies (NASDAQ: SINT) anunció una importante transición en el liderazgo, ya que el Dr. Sonny Bal se retira de su puesto como Presidente de la Junta, y el CEO Eric Olson es nombrado unánimemente como el nuevo Presidente, con efecto inmediato.
El Dr. Bal, quien ha sido Presidente desde 2015, permanecerá en la Junta de Directores para asegurar la continuidad. Bajo su liderazgo, Sintx experimentó una transformación en los sectores de materiales avanzados, enfocándose particularmente en aplicaciones médicas de alto valor y asociaciones estratégicas.
Eric Olson, quien se convirtió en CEO en agosto de 2024, aporta experiencia en los sectores de dispositivos médicos e industriales. Su nombramiento como Presidente está alineado con la estrategia de la empresa para acelerar la comercialización, mejorar la disciplina financiera y explorar iniciativas estratégicas que incluyen asociaciones, licencias y oportunidades de fusiones y adquisiciones.
신텍스 테크놀로지스 (NASDAQ: SINT)는 손니 발 박사가 이사회 의장직에서 은퇴함에 따라 중요한 리더십 전환을 발표했으며, 에릭 올슨 CEO가 새로운 의장으로 즉시 임명되었습니다.
발 박사는 2015년부터 의장직을 맡아왔으며, 지속성을 보장하기 위해 이사회에 남아 있습니다. 그의 지도 아래, 신텍스는 고급 소재 분야에서 변화가 있었으며, 특히 고부가가치 의료 응용 분야와 전략적 파트너십에 집중했습니다.
2024년 8월 CEO로 취임한 에릭 올슨은 의료 기기 및 산업 분야에서의 경험을 가지고 있습니다. 그의 의장 임명은 상업화를 가속화하고 재무 규율을 강화하며 파트너십, 라이센스 및 인수합병 기회를 포함한 전략적 이니셔티브를 탐색하려는 회사의 전략과 일치합니다.
Sintx Technologies (NASDAQ: SINT) a annoncé une transition significative au niveau de la direction, le Dr Sonny Bal se retirant de son poste de Président du Conseil, tandis que le PDG Eric Olson a été nommé à l'unanimité nouveau Président, avec effet immédiat.
Le Dr Bal, qui a été Président depuis 2015, restera au Conseil d'Administration pour garantir la continuité. Sous sa direction, Sintx a connu une transformation dans les secteurs des matériaux avancés, se concentrant particulièrement sur les applications médicales à forte valeur ajoutée et les partenariats stratégiques.
Eric Olson, qui est devenu PDG en août 2024, apporte une expérience dans les secteurs des dispositifs médicaux et industriels. Sa nomination en tant que Président s'inscrit dans la stratégie de l'entreprise visant à accélérer la commercialisation, à améliorer la discipline financière et à explorer des initiatives stratégiques, y compris des partenariats, des licences et des opportunités de fusions et acquisitions.
Sintx Technologies (NASDAQ: SINT) gab eine bedeutende Führungsänderung bekannt, da Dr. Sonny Bal von seiner Position als Vorsitzender des Vorstands zurücktritt und CEO Eric Olson einstimmig zum neuen Vorsitzenden ernannt wird, mit sofortiger Wirkung.
Dr. Bal, der seit 2015 Vorsitzender ist, wird im Vorstand bleiben, um die Kontinuität zu gewährleisten. Unter seiner Leitung durchlief Sintx eine Transformation in den Bereichen fortschrittliche Materialien, wobei der Schwerpunkt insbesondere auf hochwertigen medizinischen Anwendungen und strategischen Partnerschaften lag.
Eric Olson, der im August 2024 CEO wurde, bringt Erfahrung in den Bereichen medizinische Geräte und Industrie mit. Seine Ernennung zum Vorsitzenden steht im Einklang mit der Strategie des Unternehmens, die Kommerzialisierung zu beschleunigen, die finanzielle Disziplin zu verbessern und strategische Initiativen wie Partnerschaften, Lizenzen und M&A-Möglichkeiten zu erkunden.
- Leadership consolidation with CEO taking Chairman role, potentially streamlining decision-making
- Strategic focus on high-growth opportunities in biomedical and medical device applications
- Continued board involvement of former Chairman ensures leadership continuity
- Loss of separate Chairman and CEO roles reduces independent oversight
SALT LAKE CITY, Utah, March 17, 2025 (GLOBE NEWSWIRE) -- Sintx Technologies, Inc. (NASDAQ: SINT) (“Sintx” or the “Company”), a leader in advanced ceramics for medical device and technical applications, today announced that Dr. Sonny Bal has retired as Chairman of the Board, and the Board of Directors has unanimously appointed Eric Olson, the Company’s Chief Executive Officer, as its new Chairman, effective immediately.
Dr. Bal, who has served as Chairman since 2015, has played a crucial role in driving Sintx’s transformation, strengthening its core business, and positioning the Company for growth in the advanced materials sectors. He will continue to support the Company as a member of the Board of Directors, ensuring continuity as Sintx executes on its strategic objectives.
“On behalf of the Board and the entire Sintx team, I want to thank Sonny for his years of leadership, vision, and commitment to innovation,” said Eric Olson, CEO and newly appointed Chairman. “His guidance has helped prepare Sintx’s transition toward high-value medical applications and strategic partnerships. As we move into the next phase of execution, I am excited to lead the Company in advancing our commercial strategy, optimizing our asset portfolio, and delivering long-term value to our shareholders.”
Dr. Bal commented, “It has been an honor to serve as Chairman of Sintx Technologies and work alongside such a talented team. I am confident that under Eric’s leadership, Sintx is well-positioned for the next stage of growth, with a clear focus on unlocking the full potential of its biomaterial technology platform.”
Since being appointed CEO in August 2024, Eric Olson has refocused the Company on high-growth opportunities in biomedical and medical device applications. With a proven track record of leadership in the medical device and industrial sectors, his appointment as Chairman reinforces Sintx’s commitment to accelerating commercialization, enhancing financial discipline, and exploring strategic initiatives, including partnerships, licensing, and M&A opportunities.
For more information, please visit www.sintx.com
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
When did Eric Olson become the new Chairman of SINT?
What strategic initiatives is SINT pursuing under the new Chairman?
How long did Dr. Sonny Bal serve as SINT's Chairman?
Will Dr. Bal maintain any role with SINT after stepping down as Chairman?
